# Titan Biotech (NSE: TITANBIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/TITANBIO · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹1,793 Cr, it ranks 1195th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

Its return on equity was 16.5% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹49 Cr (+38.8% year on year) and net profit ₹7 Cr (+74.0%), on a consolidated basis. Promoters held 55.78% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹1,793 Cr |
| ROE | 16.5% (FY26) |
| ROCE | 20.8% (FY26) |
| Debt to equity | 0.02 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹49 Cr | +38.8% | ₹7 Cr | +74.0% | ₹1.63 |
| Q3 FY26 | ₹57 Cr | +47.6% | ₹8 Cr | +107.1% | ₹10.32 |
| Q2 FY26 | ₹54 Cr | +36.2% | ₹7 Cr | +37.2% | ₹9.40 |
| Q1 FY26 | ₹47 Cr | +7.9% | ₹6 Cr | +8.1% | ₹8.30 |
| Q4 FY25 | ₹35 Cr | −11.9% | ₹4 Cr | −22.1% | ₹4.90 |
| Q3 FY25 | ₹38 Cr | −16.7% | ₹4 Cr | −48.5% | ₹5.31 |
| Q2 FY25 | ₹40 Cr | −8.2% | ₹5 Cr | −17.1% | ₹8.10 |
| Q1 FY25 | ₹43 Cr | +24.1% | ₹6 Cr | +5.4% | ₹7.74 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹206 Cr | ₹27 Cr |
| FY25 | ₹156 Cr | ₹18 Cr |
| FY24 | ₹164 Cr | ₹24 Cr |
| FY23 | ₹144 Cr | ₹21 Cr |
| FY22 | ₹153 Cr | ₹29 Cr |
| FY21 | ₹142 Cr | ₹32 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 55.78%
- Domestic institutions: 0.01%
- Non-institutions: 44.21%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Hester Biosciences](https://app.pivotnow.in/stock/HESTERBIO) | ₹2,280.00 | ₹1,940 Cr | 33.7 | — |
| [Beta Drugs](https://app.pivotnow.in/stock/BETA) | ₹1,736.30 | ₹1,925 Cr | 42.5 | — |
| [Fischer Medical Ventures](https://app.pivotnow.in/stock/FISCHER) | ₹28.21 | ₹1,846 Cr | 62.7 | — |
| [Windlas Biotech](https://app.pivotnow.in/stock/WINDLAS) | ₹892.20 | ₹1,841 Cr | 28.6 | — |
| [NGL Fine-Chem](https://app.pivotnow.in/stock/NGLFINE) | ₹2,755.30 | ₹1,702 Cr | 35.3 | — |
| [Krsnaa Diagnostics](https://app.pivotnow.in/stock/KRSNAA) | ₹515.00 | ₹1,671 Cr | 16.7 | — |

## Questions and answers

### What is the market cap of Titan Biotech?

Titan Biotech's market capitalisation is ₹1,793 Cr (₹1,793 Cr) at the 19 Oct 2026 close, ranking 1195th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Titan Biotech?

Return on equity was 16.5% in FY26 and return on capital employed was 20.8% in FY26 (consolidated figures).

### Is Titan Biotech a debt-free company?

Titan Biotech is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.

### What were Titan Biotech's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Titan Biotech reported revenue of ₹49 Cr, +38.8% year on year, and net profit of ₹7 Cr, +74.0% year on year.

### What is the shareholding pattern of Titan Biotech?

As of 30 Jun 2026: promoters 55.78%, domestic institutions 0.01%, non-institutions 44.21%.

### Who are Titan Biotech's competitors?

The listed Pharma & Healthcare companies closest to Titan Biotech by market cap are Hester Biosciences, Beta Drugs, Fischer Medical Ventures, Windlas Biotech, NGL Fine-Chem and Krsnaa Diagnostics.

### Is Titan Biotech a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Titan Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TITANBIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.